Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe
Executive Summary
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
You may also be interested in...
US Generics Market Isn't Stabilizing Yet, Sandoz Says
Novartis's Sandoz unit is the first of the big generics players to report second quarter financials, and its outlook for the US market remains pessimistic.
AbbVie Defends Humira With Aggressive Discount In First EU Tender
AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.
AbbVie Defends Humira With Aggressive Discount In First EU Tender
AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.